High Mark Wealth Management LLC Genmab A/S Transaction History

High Mark Wealth Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 20, 2022	SELL	$35.87 - $47.12 $7,963 - $10,460	-222 Closed	0 $0
Q3 2021 Nov 01, 2021	SELL	$41.55 - $48.72 $664 - $779	-16 Reduced 6.72%	222 $10,000
Q2 2021 Aug 02, 2021	SELL	$32.88 - $44.57 $263 - $356	-8 Reduced 3.25%	238 $10,000
Q1 2021 Apr 22, 2021	SELL	$30.92 - $44.4 $3,772 - $5,416	-122 Reduced 33.15%	246 $8,000
Q4 2020 Jan 27, 2021	SELL	$33.66 - $40.76 $61,362 - $74,305	-1,823 Reduced 83.2%	368 $15,000
Q3 2020 Oct 26, 2020	BUY	$33.07 - $38.68 $64,850 - $75,851	1,961 Added 852.61%	2,191 $80,000
Q2 2020 Jul 22, 2020	BUY	$20.05 - $33.89 $4,611 - $7,794	230 New	230 $8,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of High Mark Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on High Mark Wealth Management LLC with notifications on news.